Market Cap 34.43M
Revenue (ttm) 6.34M
Net Income (ttm) -58.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -918.61%
Debt to Equity Ratio 0.00
Volume 224,900
Avg Vol 589,462
Day's Range N/A - N/A
Shares Out 52.50M
Stochastic %K 5%
Beta -0.06
Analysts Sell
Price Target $2.00

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 524 2466
Website: xiliotx.com
Address:
828 Winter Street, Suite 300, Waltham, United States
8_seconds
8_seconds Jan. 14 at 10:43 PM
$XLO trying to just forget about this buy and chalk it up as a complete loss. If something ever does happen, great. Not like I have a huge number of shares anyway. Still sucks though
0 · Reply
killer_7
killer_7 Jan. 13 at 10:57 PM
$XLO adding here
0 · Reply
809trader
809trader Jan. 13 at 2:38 PM
$SGMO Sold half of my position here on $SGMO keeping some shares and all my calls. Adding to my $XLO position making it my biggest holding. PS. FUCK YOU SANDY 🐷
1 · Reply
809trader
809trader Jan. 13 at 12:33 AM
$XLO this is a great sign. LFG 🥳🥳🥳
0 · Reply
ezimon
ezimon Jan. 12 at 5:14 PM
$XLO WOW got vertigo!!!
0 · Reply
love_bioatla
love_bioatla Jan. 10 at 6:44 AM
$XLO boom up
0 · Reply
Jtlo
Jtlo Jan. 9 at 12:57 PM
$XLO locked in. Playing the compliance game. Good start
0 · Reply
biohuntress
biohuntress Jan. 9 at 12:04 AM
$XLO https://xiliotx.gcs-web.com/news-releases/news-release-details/xilio-therapeutics-highlights-upcoming-milestones-and-recent
0 · Reply
AllandaleCapital
AllandaleCapital Jan. 8 at 2:52 PM
$XLO what are some small biotechs with heavy LP presence that have ended up doing a R/S?
0 · Reply
AllandaleCapital
AllandaleCapital Jan. 8 at 2:26 PM
$XLO needs $1 compliance by 3/30/26, live short interest 24.13%, CTB 18.05, LP crawling all over Pre-funded warrants (mostly $0.01 strike): ~132M Low-strike 0.75 warrants (A/B/C): ~133M Total derivative overhang: ~265M shares “Economic” fully diluted share count: ~330M+ vs today’s 67.5M. OS: 67.54M Float: 62.63M Market Cap: ~$48.3M Key Dilution Weapons Active • June 2025 Unit Deal (Leerink) – 66.68M common @ $0.75 – 66.68M Series A warrants @ $0.75 (5-yr) – 66.68M Series B warrants @ $0.75 (short-dated, into Dec 2025) – 66.68M Series C warrants @ $0.75 (into Dec 2026) – Matching 66.68M pre-funded warrants @ $0.01 (0.75 cost) – $50.0M gross proceeds • Pre-Funded Warrant Stack (functionally common) – June 2025 pre-funded: 66.68M @ $0.01 (paid $0.75) – December 2025 pre-funded: 40.01M @ $0.01 (0.75 cost) – March 2024 PIPE pre-funded: 19.51M @ $0.01 (0.64 cost, Bain/Rock Springs/Gilead) – December 2024 Gilead pre-funded: 6.09M @ $1.04 – Total pre-funded overhang ~132M shares, essentially already “paid for.” • ATM + Shelf (Dry Powder) – March 2025 ATM (Leerink): $50.0M capacity, unused – March 2025 Shelf: $50.0M raisable; prior shelves still largely unused as well – No baby shelf restriction (float value >$50M), so they can tap size if they want. Completed Dilutive Events (most relevant recent) December 2, 2025 – Warrant Exercise • 48.21M shares @ $0.75 (Series C) • $36.16M raised June 2, 2025 – Underwritten S-3 (Leerink unit deal) • 66.68M shares @ $0.75 • 200.03M warrants (A/B/C) + 66.68M pre-funded • $50.0M raised February 10, 2025 – AbbVie PIPE • 4.35M shares @ $2.30 • $10.0M raised December 19, 2024 – Gilead PIPE • 7.85M shares @ $1.04 (+ pre-funded structure via Dec 2024 warrants) • $8.17M raised March 28, 2024 – Bain / Rock Springs / Gilead • 17.57M shares @ $0.64 (Bain, Rock Springs) • 6.85M shares @ $1.97 (Gilead) • $24.8M raised + $30M upfront from Gilead license Most Dangerous Instruments • Pre-funded warrants @ $0.01 – ~132M shares at effectively zero incremental cost. – Economically the same as common stock that can hit the tape whenever there’s liquidity. • 0.75 Strike Warrant Stack (Series A/B/C) – ~133M warrants @ $0.75 still outstanding. – Once stock sustains >$0.75 with volume, every rally is monetizable via cheap paper. Deal Memory (Price Levels That Matter) $16.00 – IPO (2021) $2.30 – AbbVie PIPE (Feb 2025) $1.97 – Gilead PIPE (Mar 2024) $1.04 – Gilead Dec 2024 follow-on / pre-funded cost $0.75 – June 2025 recap unit price (shares + A/B/C + pre-funded) $0.64 – Bain / Rock Springs PIPE $0.70–$0.75 – Current trading band vs warrant wall
1 · Reply
Latest News on XLO
Xilio Therapeutics Announces Proposed Public Offering

Jun 2, 2025, 6:11 AM EDT - 8 months ago

Xilio Therapeutics Announces Proposed Public Offering


8_seconds
8_seconds Jan. 14 at 10:43 PM
$XLO trying to just forget about this buy and chalk it up as a complete loss. If something ever does happen, great. Not like I have a huge number of shares anyway. Still sucks though
0 · Reply
killer_7
killer_7 Jan. 13 at 10:57 PM
$XLO adding here
0 · Reply
809trader
809trader Jan. 13 at 2:38 PM
$SGMO Sold half of my position here on $SGMO keeping some shares and all my calls. Adding to my $XLO position making it my biggest holding. PS. FUCK YOU SANDY 🐷
1 · Reply
809trader
809trader Jan. 13 at 12:33 AM
$XLO this is a great sign. LFG 🥳🥳🥳
0 · Reply
ezimon
ezimon Jan. 12 at 5:14 PM
$XLO WOW got vertigo!!!
0 · Reply
love_bioatla
love_bioatla Jan. 10 at 6:44 AM
$XLO boom up
0 · Reply
Jtlo
Jtlo Jan. 9 at 12:57 PM
$XLO locked in. Playing the compliance game. Good start
0 · Reply
biohuntress
biohuntress Jan. 9 at 12:04 AM
$XLO https://xiliotx.gcs-web.com/news-releases/news-release-details/xilio-therapeutics-highlights-upcoming-milestones-and-recent
0 · Reply
AllandaleCapital
AllandaleCapital Jan. 8 at 2:52 PM
$XLO what are some small biotechs with heavy LP presence that have ended up doing a R/S?
0 · Reply
AllandaleCapital
AllandaleCapital Jan. 8 at 2:26 PM
$XLO needs $1 compliance by 3/30/26, live short interest 24.13%, CTB 18.05, LP crawling all over Pre-funded warrants (mostly $0.01 strike): ~132M Low-strike 0.75 warrants (A/B/C): ~133M Total derivative overhang: ~265M shares “Economic” fully diluted share count: ~330M+ vs today’s 67.5M. OS: 67.54M Float: 62.63M Market Cap: ~$48.3M Key Dilution Weapons Active • June 2025 Unit Deal (Leerink) – 66.68M common @ $0.75 – 66.68M Series A warrants @ $0.75 (5-yr) – 66.68M Series B warrants @ $0.75 (short-dated, into Dec 2025) – 66.68M Series C warrants @ $0.75 (into Dec 2026) – Matching 66.68M pre-funded warrants @ $0.01 (0.75 cost) – $50.0M gross proceeds • Pre-Funded Warrant Stack (functionally common) – June 2025 pre-funded: 66.68M @ $0.01 (paid $0.75) – December 2025 pre-funded: 40.01M @ $0.01 (0.75 cost) – March 2024 PIPE pre-funded: 19.51M @ $0.01 (0.64 cost, Bain/Rock Springs/Gilead) – December 2024 Gilead pre-funded: 6.09M @ $1.04 – Total pre-funded overhang ~132M shares, essentially already “paid for.” • ATM + Shelf (Dry Powder) – March 2025 ATM (Leerink): $50.0M capacity, unused – March 2025 Shelf: $50.0M raisable; prior shelves still largely unused as well – No baby shelf restriction (float value >$50M), so they can tap size if they want. Completed Dilutive Events (most relevant recent) December 2, 2025 – Warrant Exercise • 48.21M shares @ $0.75 (Series C) • $36.16M raised June 2, 2025 – Underwritten S-3 (Leerink unit deal) • 66.68M shares @ $0.75 • 200.03M warrants (A/B/C) + 66.68M pre-funded • $50.0M raised February 10, 2025 – AbbVie PIPE • 4.35M shares @ $2.30 • $10.0M raised December 19, 2024 – Gilead PIPE • 7.85M shares @ $1.04 (+ pre-funded structure via Dec 2024 warrants) • $8.17M raised March 28, 2024 – Bain / Rock Springs / Gilead • 17.57M shares @ $0.64 (Bain, Rock Springs) • 6.85M shares @ $1.97 (Gilead) • $24.8M raised + $30M upfront from Gilead license Most Dangerous Instruments • Pre-funded warrants @ $0.01 – ~132M shares at effectively zero incremental cost. – Economically the same as common stock that can hit the tape whenever there’s liquidity. • 0.75 Strike Warrant Stack (Series A/B/C) – ~133M warrants @ $0.75 still outstanding. – Once stock sustains >$0.75 with volume, every rally is monetizable via cheap paper. Deal Memory (Price Levels That Matter) $16.00 – IPO (2021) $2.30 – AbbVie PIPE (Feb 2025) $1.97 – Gilead PIPE (Mar 2024) $1.04 – Gilead Dec 2024 follow-on / pre-funded cost $0.75 – June 2025 recap unit price (shares + A/B/C + pre-funded) $0.64 – Bain / Rock Springs PIPE $0.70–$0.75 – Current trading band vs warrant wall
1 · Reply
LesterDiamond99
LesterDiamond99 Jan. 6 at 4:51 PM
$XLO Percolating…
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 3:21 AM
$XLO keeping it real casual!
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 1:20 AM
$XLO Exercise of warrants https://www.rapidticker.com/news/xlo-sec-filing-5670ef
0 · Reply
Stmkr
Stmkr Jan. 5 at 1:40 PM
$XLO "As of January 2, 2026, there were 67,540,930 shares of the Company’s common stock issued and outstanding, including shares of common stock issued in connection with the exercise of the Series B warrants and the exercise of certain previously issued prefunded warrants for common stock. Based on its current operating plans, the Company anticipates that its existing cash and cash equivalents, together with the net proceeds from the exercise of the Series B warrants, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2027."
0 · Reply
MarketReaper
MarketReaper Dec. 31 at 4:19 AM
$XLO If it gets in the 50s I will buy some more, giddy up!
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 6:05 PM
0 · Reply
BiotechValues
BiotechValues Dec. 30 at 5:16 PM
$BCAB Don't let the fraudster below try and scare you out of your shares. BCAB has to keep voting for a R/S for long-term insurance. Below is what happened to $XLO on their deal with GILD. Spiked 200% and a month later dipped back under $1. Weekly chart below:
1 · Reply
IceBison
IceBison Dec. 30 at 4:48 PM
$XLO if data isn't good enough, $GILD didn't increase it's stake from 10% to 20% maximum https://www.sec.gov/edgar/search/#/ciks=0001840233&entityName=Xilio%2520Therapeutics%252C%2520Inc.%2520(XLO)%2520(CIK%25200001840233)
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 30 at 6:30 AM
$XLO RSI: 18.75, MACD: -0.0261 Vol: 0.03, MA20: 0.69, MA50: 0.74 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LamentationsL
LamentationsL Dec. 27 at 5:42 AM
$XLO Investor attention is skewing toward repeatable operating performance instead of aspirational projections. Resource allocation choices will signal strategic maturity. Missteps now carry a higher penalty than in prior cycles. Momentum becomes sustainable only when delivery keeps pace.
1 · Reply
ThirstyFishy
ThirstyFishy Dec. 27 at 2:33 AM
$XLO this is a sad little stock. Come here, little battered, neglected, doesn't know what's good or bad for it little stock. Daddy's here for some risky shares
1 · Reply
IceBison
IceBison Dec. 27 at 2:08 AM
$XLO if company needs to reserve split stock, company must let stockholders vote in meeting but I don't see any vote so I expect a positive news to pump stock over $1 before deadline.
0 · Reply